Cutler Group’s Foghorn Therapeutics FHTX Stock Holding History

Cutler Group’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,000	Closed	-$23K	–	5536
2021 Q4	$23K	Buy	+25,000	New	+$359K	﹤0.01%	3007

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cutler Group's FHTX Position: Q2 2022 in Review

Cutler Group sold out of Foghorn Therapeutics (FHTX) in Q2 2022, closing a stake of 600 shares — an estimated $9K sold.

Cutler Group first reported a position in FHTX in Q4 2021 and held it in 2 quarters. The position peaked at $85K in Q4 2021. 60 funds tracked by Wall St. Rank hold FHTX as of Q2 2022.

Cutler Group reported no remaining Foghorn Therapeutics position as of Q2 2022 after selling out during the quarter.
Cutler Group sold 600 Foghorn Therapeutics shares in Q2 2022, an estimated $9K.
Cutler Group first reported a position in Foghorn Therapeutics in Q4 2021 and held it in 2 quarters.
Cutler Group's Foghorn Therapeutics position peaked at $85K in Q4 2021.
60 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.